REGENXBIO Inc.
RGNX · NASDAQ
Analyst ratings
strong_buy · 10 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| June 24, 2026 | HC Wainwright & Co. | Reiterates | Buy | $26.00 |
| June 22, 2026 | Baird | Maintains | Outperform | $32.00 |
| June 22, 2026 | Leerink Partners | Maintains | Outperform | $18.00 |
| June 5, 2026 | HC Wainwright & Co. | Maintains | Buy | $26.00 |
| May 15, 2026 | B of A Securities | Maintains | Buy | $14.00 |
| May 15, 2026 | Barclays | Maintains | Overweight | $12.00 |
| March 9, 2026 | HC Wainwright & Co. | Maintains | Buy | $30.00 |
| March 6, 2026 | Morgan Stanley | Maintains | Overweight | $17.00 |
| February 10, 2026 | HC Wainwright & Co. | Maintains | Buy | $32.00 |
| February 10, 2026 | Goldman Sachs | Maintains | Neutral | $12.00 |
| February 10, 2026 | Morgan Stanley | Maintains | Overweight | $18.00 |
| February 10, 2026 | Chardan Capital | Maintains | Buy | $50.00 |
| January 29, 2026 | Chardan Capital | Maintains | Buy | $52.00 |
| December 19, 2025 | Stifel | Maintains | Buy | $45.00 |
| December 15, 2025 | Leerink Partners | Maintains | Outperform | $20.00 |
| November 20, 2025 | Chardan Capital | Maintains | Buy | $52.00 |
| November 7, 2025 | RBC Capital | Maintains | Outperform | $19.00 |
| October 7, 2025 | HC Wainwright & Co. | Reiterates | Buy | $34.00 |
| September 8, 2025 | HC Wainwright & Co. | Reiterates | Buy | $34.00 |
| September 8, 2025 | Chardan Capital | Maintains | Buy | $52.00 |
RGX-202 Duchenne muscular dystrophy (DMD) program viability and commercial potential
The DMD gene therapy pipeline, particularly RGX-202, is seen as a strong value driver. Pivotal trial enrollment surpassed 50%, commercial manufacturing was initiated, and recent Duchenne data reinforced confidence in the NAV technology platform. Comparable therapies are priced around $3.2 million as one-time treatments, suggesting significant revenue potential.
Despite pipeline progress, REGENXBIO posted a massive revenue miss — $6.39 million versus $25.84 million estimated — and an EPS miss of -$1.72 versus -$1.36 expected. The persistent clinical-stage losses and negative EPS growth forecast of -32.40% over five years cast doubt on near-term commercial execution and financial sustainability.
Financial stability and bankruptcy risk amid ongoing cash burn
Despite current losses, analysts broadly maintain a 'Strong Buy' or 'Moderate Buy' consensus, with average price targets ranging from $23.82 to $34.00 — implying over 100% upside. The projected five-year revenue growth of 50.45% suggests analysts expect the company's pipeline to eventually generate substantial commercial revenues.
REGENXBIO carries an alarming Altman Z-Score of -1.78 and a Piotroski F-Score of just 3, both signaling elevated financial distress and increased bankruptcy risk. The company's persistent negative EPS, widening quarterly losses, and a price-to-earnings ratio of -1.78 raise serious concerns about long-term financial viability without additional capital.
Analyst price target divergence and stock valuation credibility
Major institutions including HC Wainwright, Leerink Partners, and Barclays maintain 'Buy' or 'Outperform' ratings, with targets ranging from $18.00 to $52.00. The broad consensus of 10 Buy ratings versus just 2 Sells reflects strong institutional confidence that current prices severely undervalue the company's gene therapy assets.
The extreme spread between the lowest ($14.00) and highest ($52.00) price targets reveals deep uncertainty about intrinsic value. Bank of America slashed its target from $25.00 to $14.00, and Barclays cut from $37.00 to $12.00 following earnings, reflecting a crisis of confidence in near-term revenue forecasts and execution reliability.